BeiGene, SpringWorks to Study Combination Therapy for Advanced Solid Tumors

BeiGene’s RAF dimer inhibitor lifirafenib (BGB-283) and SpringWorks Therapeutics’ MEK inhibitor, PD-0325901 will be studied as a combination therapy for patients with advanced solid tumors in a trial set to start next year, the companies said.The value of the collaboration was not disclosed—though the companies did say that they will equally share all costs of their clinical studies and governance responsibilities. BeiGene has agreed to administer a Phase Ib trial that is expec